In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

With the current stock turmoil, global stocks, and especially stocks that pay dividends, are a potential option for investors. While the S&P 500 has fallen 12% year to date, the EAFE Index of large- and mid-cap stocks based in countries other than the U.S. and Canada has gained 1%. That's quite a change from the recent record. Over the past five years, the S&P 500 has advanced 109% compared to a 50% gain in EAFE. But the underperformance has given global stocks a valuation advantage, particularly in the area of dividends. Consider that the EAFE dividend yield of 3.0% is roughly 175 basis points higher than the comparable S&P 500 dividend yield. We think global dividend stocks continue to offer opportunity, particularly given the endless speculation over the direction of interest rates in the U.S., which has created market-timing headaches for equity income investors. These investors have endured recent wide swings in prices for rate-sensitive equity groups such as utilities, REITs and MLPs. In our view, investing in international income stocks is one way to increase portfolio diversification while reducing sensitivity to volatile U.S interest rates. Investing in overseas stocks carries its own set of risks, including the impact of currency exchange and geopolitical turmoil. But there are also a number of positives in this asset class for U.S. investors, including a wide selection of companies that pay dividends, robust industry diversification, and, as we have mentioned, higher yields and lower valuations. Argus has recently boosted its global coverage, and recommends the following international dividend stocks, each of which has at least a long-term BUY rating from an Argus analyst. This list of approximately 25-30 companies offers exposure to eight of the 11 major industrial sectors, and includes companies from 10 countries.

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK plc, based in Brentford, UK, is a global healthcare company engaged in the discovery, development, manufacture and marketing of pharmaceutical products. The company's leading products include treatments for asthma and COPD; products for HIV infection; and a range of vaccines. The company has active research and development programs in immuno-inflammation, neuroscience, metabolic pathways, ophthalmology, respiratory and infectious diseases, and biopharmaceuticals.